Trial · NCT07913893
Multicomponent Exercise and Pain Neuroscience Education in Women With Fibromyalgia
NCT07913893, Not applicable, Completed, Cristian Omar Gálvez Rodríguez
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Multicomponent Exercise and Pain Neuroscience Education in Women With Fibromyalgia. Trials, record NCT07913893. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913893
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multicomponent Exercise and Pain Neuroscience Education in Women With Fibromyalgia
- NCT number
- NCT07913893
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 26 participants, actual
- Lead sponsor
- Cristian Omar Gálvez Rodríguez
- Conditions
- Fibromyalgia
- Interventions
- Multicomponent Exercise
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in 1-Minute Sit-to-Stand Test Performance | Baseline (Week 0), Week 6, and Week 12 | Lower-limb functional performance was assessed using the 1-minute sit-to-stand test (1-min STS). Participants were instructed to complete as many full sit-to-stand repetitions as possible in 60 seconds using a standardized armless chair. The outcome was the number of correctly completed repetitions. Higher values indicate better functional performance. Changes were assessed across three time points. |
| Primary | Change in Dominant-Hand Handgrip Strength | Baseline (Week 0), Week 6, and Week 12 | Handgrip strength was measured using a Jamar hydraulic hand dynamometer. Three maximal voluntary contraction trials were performed with the dominant hand, with rest intervals between attempts. The highest recorded value was used for analysis and expressed in kilograms (kg). Higher values indicate greater handgrip strength. Changes were assessed across three time points. |
| Secondary | Change in Pain Intensity (Numeric Rating Scale) | Baseline (Week 0), Week 6, and Week 12 | Pain intensity measured using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes from baseline were planned to be assessed at weeks 6 and 12. |
| Secondary | Change in Fibromyalgia Impact (FIQR) | Baseline (Week 0), Week 6, and Week 12 | Fibromyalgia impact assessed using the Revised Fibromyalgia Impact Questionnaire (FIQR). The total score ranges from 0 to 100 and reflects physical function, overall impact, and symptoms. Higher scores indicate greater disease impact and worse health status. |
| Secondary | Change in Health-Related Quality of Life (SF-36) | Baseline (Week 0), Week 6, and Week 12 | Health-related quality of life assessed using the 36-Item Short Form Health Survey (SF-36). Eight health domains are scored from 0 to 100. Higher scores indicate better perceived health status. Changes in domain scores were planned to be assessed over time. |
| Secondary | Change in Sleep Quality (Pittsburgh Sleep Quality Index) | Baseline (Week 0), Week 6, and Week 12 | Sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI). The global score ranges from 0 to 21, calculated from seven components of sleep quality. Higher scores indicate poorer sleep quality. |
| Secondary | Change in Multidimensional Fatigue (MFI-20) | Baseline (Week 0), Week 6, and Week 12 | Fatigue assessed using the 20-item Multidimensional Fatigue Inventory (MFI-20), which measures general fatigue, physical fatigue, mental fatigue, reduced activity, and reduced motivation. Each subscale ranges from 4 to 20, with higher scores indicating greater fatigue or impairment. |
| Secondary | Change in Physical Activity Level (IPAQ-SF) | Baseline (Week 0), Week 6, and Week 12 | Self-reported physical activity assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). Walking, moderate-intensity, and vigorous-intensity activities during the preceding seven days are used to classify physical activity as low, moderate, or high according to IPAQ scoring guidelines. |
| Secondary | Change in Pain Catastrophizing (PCS) | Baseline (Week 0), Week 6, and Week 12 | Pain-related catastrophic thinking assessed using the Pain Catastrophizing Scale (PCS). The total score ranges from 0 to 52 and includes rumination, magnification, and helplessness components. Higher scores indicate greater pain catastrophizing. |
| Secondary | Change in Fear of Movement (TSK-11) | Baseline (Week 0), Week 6, and Week 12 | Fear of movement and reinjury assessed using the 11-item Tampa Scale for Kinesiophobia (TSK-11). Total scores range from 11 to 44. Higher scores indicate greater fear of movement. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913893
GET https://conductscience.org/api/trials/v1/NCT07913893/registered